April 2025 in “Vestnik dermatologii i venerologii” JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.
October 2022 in “Journal of Armed Forces Medical College, Bangladesh” Tofacitinib is effective and safe for treating alopecia areata.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
3 citations
,
May 2023 in “International Journal of Molecular Sciences” A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
February 2025 in “International Journal of STD & AIDS” Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
13 citations
,
September 2014 in “BMC Complementary and Alternative Medicine” Tanshinone IIA helps protect skin tissue from low oxygen damage by boosting certain cell markers.
19 citations
,
April 2016 in “Case Reports in Dermatology” Nilotinib can cause keratosis pilaris, a skin condition.
5 citations
,
September 2020 in “Proceedings - Baylor University. Medical Center” Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
22 citations
,
May 2011 in “European Journal of Cancer” The drug combination was safe and showed promise in treating advanced tumors.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
8 citations
,
September 2013 in “Molecular carcinogenesis” Rapamycin reduces skin cell growth and tumor development by affecting cell signaling in mice.
5 citations
,
May 2023 in “Clinical Rheumatology” Tofacitinib helped regrow hair in a lupus patient with alopecia.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
4 citations
,
January 2022 in “Dermatologic Therapy” Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
August 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
196 citations
,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
2 citations
,
January 2025 in “Journal of Clinical Immunology” 13 citations
,
January 2020 in “Acta Dermato Venereologica” Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
2 citations
,
November 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.
5 citations
,
May 2011 in “Movement Disorders” Finasteride may help reduce tic severity in male Tourette syndrome patients.